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A mouse model of prenatal
exposure to Interleukin‑6 to study
the developmental origin of health
and disease
Tarak Srivastava1,2,3*, Trupti Joshi4,5,6,7, Daniel P. Heruth8, Mohammad H. Rezaiekhaligh1,
Robert E. Garola9, Jianping Zhou2,10, Varun C. Boinpelly2,10, Mohammed Farhan Ali1,
Uri S. Alon1, Madhulika Sharma11, Gregory B. Vanden Heuvel12, Pramod Mahajan13,
Lakshmi Priya1, Yuexu Jiang5,6, Ellen T. McCarthy11, Virginia J. Savin10,11, Ram Sharma10 &
Mukut Sharma2,10,11
Systemic inflammation in pregnant obese women is associated with 1.5- to 2-fold increase in serum
Interleukin-6 (IL-6) and newborns with lower kidney/body weight ratio but the role of IL-6 in increased
susceptibility to chronic kidney (CKD) in adult progeny is not known. Since IL-6 crosses the placental
barrier, we administered recombinant IL-6 (10 pg/g) to pregnant mice starting at mid-gestation
yielded newborns with lower body (p < 0.001) and kidney (p < 0.001) weights. Histomorphometry
indicated decreased nephrogenic zone width (p = 0.039) with increased numbers of mature glomeruli
(p = 0.002) and pre-tubular aggregates (p = 0.041). Accelerated maturation in IL-6 newborns was
suggested by early expression of podocyte-specific protein podocin in glomeruli, increased 5-methylcytosine (LC–MS analysis for CpG DNA methylation) and altered expression of certain genes of cellcycle and apoptosis (RT-qPCR array-analysis). Western blotting showed upregulated pJAK2/pSTAT3.
Thus, treating dams with IL-6 as a surrogate provides newborns to study effects of maternal systemic
inflammation on future susceptibility to CKD in adulthood.
The increasing global prevalence of chronic kidney disease (CKD) and obesity is associated with chronic inflammation identified by elevated pro-inflammatory cytokines including serum interleukin 6 (IL-6)1–4. Recent epidemiological studies have shown that maternal overweight/obesity is associated with low kidney volume/birth
weight ratio, increased incidence of CKD, and increased risk for congenital anomalies in their c hildren5–11. These
observations suggest that maternal obesity (gestational inflammation) alters the intrauterine environment affecting kidney development (fetal programming), which may predispose the offspring to increased susceptibility
to CKD in adulthood.
The developmental origin of health and disease hypothesis (or Barker’s hypothesis) suggests that perinatal
events influence the genesis of a disease, such as CKD in adulthood12. In the framework of a ‘two-hit’ model,
changes in fetal kidney programming becomes the ‘first hit’, and any subsequent injury in the form of loss of one
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kidney due to trauma or tumor, obesity, malnutrition, etc. results in the ‘second hit’. Thus, the changes induced by
the ‘first hit’ influence the course and outcome of kidney disease from the ‘second hit’13,14. Lack of a convenient
animal model is one of the reasons for our limited understanding on the effects of maternal systemic inflammation in causing impairment of kidney development and long-term susceptibility to CKD in the progeny. Hence,
we explored the use of prenatal treatment of pregnant mice to a pro-inflammatory cytokine (IL-6) as a surrogate
of maternal (gestational) inflammation.
The placental barrier separates the maternal and fetal compartments, and regulates transfer of specific maternal proteins (e.g., certain immunoglobulins) to the fetal compartment15. Others have shown that, among the
inflammatory cytokines associated with obesity (IL-6, TNFα, IL-1β), only maternal IL-6 crosses the placental
barrier starting in mid-gestation16–18. Since serum IL-6 is elevated 1.5–2-fold in pregnant obese women compared
to non-obese pregnant women, we postulated that transfer of increased maternal IL-6 may alter kidney fetal
programming and initiate the ‘first hit’ in a chain of pro-inflammatory c hanges19–21.
Here we show that prenatal administration of IL-6 to pregnant mice resulted in offspring with decreased birth
weight, decreased kidney weight, and accelerated maturation of the developing kidney. Since CKD is associated
with glomerular dysfunction resulting in albuminuria/proteinuria22,23, we tested the direct effect of IL-6 on the
glomerular filtration barrier function. We found that incubation with IL-6 resulted in derangement of cultured
podocyte cytoskeleton and increased glomerular albumin permeability in vitro.
Our approach permits controlled dosing of IL-6 starting in mid-gestation, yields sufficient number of newborns for studies and permits clear interpretation of results for establishing specific causal relationship between
maternal systemic inflammation and fetal kidney development. We propose that newborns from mothers treated
with IL-6 will be a convenient mouse model to study the long-term effects of maternal systemic inflammation
during pregnancy and investigate susceptibility to CKD following a second injury in adult progeny in future
studies.

Results

We evaluated the effect of intraperitoneal injection of IL-6 to pregnant mice starting in mid-gestation to study
its in vivo effect on intrauterine kidney development and performed in vitro experiments to determine whether
IL-6 directly (1) impairs the glomerular filtration barrier function, (2) affects the podocyte actin cytoskeleton,
changes that precede overt proteinuria and, (3) hampers metanephric kidney growth in culture. Results outlined
below suggest that IL-6 has direct effect on fetal kidney development and on glomerular filtration barrier. These
effects of IL-6 during kidney development may have long-term impact and increase the susceptibility to CKD
in the adult offspring.

Interleukin‑6 administration to pregnant dam had no detrimental effect on the mother.

Intraperitoneal (IP) administration of IL-6 at 10 pg/g BWT, every other day from E12.5 to end of gestation (E20 ± 0.5)
to timed-pregnant C57BL/6 mice had no detrimental effect on the mother. There were no miscarriages or deaths
in pregnant dams. We did not observe decreased food/water intake, decreased activity or decreased grooming
in the IL-6 injected pregnant dams.

IL‑6 administration to pregnant mice resulted in smaller newborns and smaller kidneys.

Figure 1A–D shows the results of mid-gestation intraperitoneal (IP) administration of IL-6 (10 pg/g BWT, every
other day from E12.5 to end of gestation (E20 ± 0.5) to timed-pregnant C57BL/6 mice. A total of 53 pups (27
female and 26 male) were born to control dams (n = 6) and 48 pups (24 female and 24 male) to IL-6 treated
dams (n = 6). IL-6 treatment did not result in mortality or affect the number of male or female newborns (Supplementary Table S1). The pups born to IL-6 treated dams appeared normal except being smaller compared to
pups born to control dams (Fig. 1A). The mean ± SD birth weight was lower in pups born to IL-6 treated dams
(1.144 g ± 0.121, n = 48) compared to control dams (1.282 g ± 0.111, n = 53; p < 0.001). The ratio of body weight
between the Control and IL-6 groups was 1:0.89.
Figure 1C shows the box-plot distribution of newborn body weight by sex. The difference between the Control
and IL-6 groups for body weight for female pups was 1.277 g ± 0.093, n = 27 vs. 1.129 g ± 0.093, n = 24, p < 0.001
and male pups was 1.286 g ± 0.128, n = 26 vs. 1.158 g ± 0.145, n = 24, p = 0.0017. Within each group, body weights
of male and female (male:female) pups were comparable i.e., Control group (1:0.99, p = 0.77) and IL-6 group
(1:0.98, p = 0.43).
Every newborn had two kidneys, but the kidneys were smaller in pups born to IL-6 treated dams as compared to the pups born to control dams (Fig. 1B). The kidney weight (mean ± SD) was lower in pups born to
IL-6 treated dams (0.0059 g ± 0.0009, n = 48) compared to the control group (0.0069 g ± 0.0011, n = 53; p < 0.001).
The kidney weight ratio between the Control and IL-6 groups was 1:0.86 (Control:IL-6). Similar observation
was made regarding weights of left and right kidneys. Thus, the left and right kidney weight ratios were 1:0.89
(Control:IL-6 groups) and 1:0.84 (Control:IL-6 groups), respectively.
Figure 1D shows the box-plot distribution of mean kidney weight by sex. The difference between the Control and IL-6 groups for kidney weight of female pups was significant at p < 0.001 (0.0069 g ± 0.0010, n = 27 vs.
0.0058 g ± 0.0009, n = 24) and that of male pups was p = 0.002 (0.0070 g ± 0.0011, n = 26 vs. 0.0061 g ± 0.0007,
n = 24). Within each respective group, there was no sex difference in fetal kidney weight between male pups and
female pups within the control group (1:0.99, p = 0.86) and IL-6 group (1:0.96, p = 0.32).
The data was also analyzed using all newborns from each dam as a single dataset point. The results were
essentially unchanged. The mean ± SD birth weight was lower in pups born to IL-6 treated dams (1.138 g ± 0.102,
n = 6) compared to control dams (1.276 g ± 0.078, n = 6; p = 0.025). The ratio of body weight between the Control
and IL-6 groups was 1:0.89. The difference between the Control and IL-6 groups for body weight of female pups
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Figure 1.  IL-6 treatment alters kidney growth in vivo and in vitro. (A) Representative images newborns and (B) newborn kidneys
from control dams and those treated with IL-6 (10 pg/g BWT, ip) every other day (E12.5–E20). Maternal IL-6 treatment resulted in
smaller body size and kidneys in the newborn compared to pups born to control dams. Box plots show the distribution of (C) body
weights and (D) kidneys by sex. Body and kidney weights in both sexes were significantly different between control (n = 53) and
IL-6 groups (n = 48) (see text for details). (E) Mouse fetal metanephroi isolated at E13.5 were grown in vitro with 10 pg/mL (IL-6)
or without (Control) for 0, 24, 48 and 72 h. IL-6 caused decrease in the growth of metanephric kidneys determined by reduction in
surface area.
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Figure 2.  Gestational administration of IL-6 to dams results in upregulation of JAK/STAT pathway in newborn
kidneys. Western blot analysis showing changes in phosphorylation of JAK2, STAT3 and STAT5 in kidneys
of pups born to dams treated with saline (Control) versus IL-6. Kidneys all newborns from each dam (n = 2,
kidneys from 6 to 8 pups included in each sample) were pooled to obtain protein lysate for the Western blot.
Increased phosphorylation of JAK2 and STAT3 but not STAT5 was observed. β-Actin was used as the loading
control.

was 1.263 g ± 0.070, n = 6 vs. 1.124 g ± 0.077, n = 6, p = 0.008 and that of male pups was 1.295 g ± 0.095, n = 6 vs.
1.161 g ± 0.133, n = 6, p = 0.074. The kidney weight (mean ± SD) was lower in pups born to IL-6 treated dams
(0.0060 g ± 0.0004, n = 6) compared to the control group (0.0069 g ± 0.0008, n = 6; p = 0.037). The kidney weight
ratio between the Control and IL-6 groups was 1:0.87 (Control:IL-6).The difference between the Control and
IL-6 groups for body weight of female pups was 0.0068 g ± 0.0007, n = 6 vs. 0.0059 g ± 0.0003, n = 6, p = 0.024 and
male pups was 0.0070 g ± 0.0009, n = 6 vs. 0.0061 g ± 0.0005, n = 6), p = 0.073. The boxplot distribution is shown
as Supplementary Figure S1.
The kidney weight/body weight ratio was lower but not significant in pups born to IL-6 treated dams
(0.0052 ± 0.0006, n = 48) compared to the control group (0.0054 ± 0.0006, n = 53; p = 0.09). The kidney weight/
body weight ratio in pups born to IL-6 treated dams (0.0052 ± 0.0002, n = 6) was similar to the control group
(0.0053 ± 0.0004, n = 6; p = 0.61).
Figure 1E shows the growth of metanephroi (E13.5) incubated with IL-6 (10 pg/mL) for up to 72 h. Morphometric analysis using NIH Image J software for calculating surface area at 0, 24, 48 and 72 h showed that
the surface area of the Control group increased by 37% and that of the IL-6 group by 30%. Tissue growth ratio
between the Control and IL-6 groups was 1:0.81. Thus, IL-6 attenuated the growth of developing metanephroi
in vitro and fetal kidney in vivo by ~ 15–20%.

Gestational IL‑6 administration to dams resulted in upregulation of JAK‑STAT pathway in
newborn kidneys. Newborn kidneys were pooled to obtain protein lysates for Western blot analysis. Each

lane represents pooled newborn kidneys from one dam in Fig. 2. Results show that injection of IL-6 to pregnant mice resulted in increased phosphorylation of JAK2 (Tyr1007) and STAT3 (Tyr705) in the newborn kidneys. These results corroborate the data obtained from similar experiments using podocyte cultures (vide infra,
Fig. 9). Interestingly, IL-6 has opposite effects on pSTAT3 and pSTAT5 phosphorylation in kidneys at birth
underscoring differences in STAT isoforms. These results show a definitive upregulated JAK-STAT signaling in
developing kidneys caused by IL-6 injected to mothers.

Newborn kidney morphology suggests accelerated maturation following IL‑6 exposure dur‑
ing gestational development. Figure 3A–D captures the results of various morphological parameters of

the newborn kidneys to highlight the effect of maternal IL-6. Figure 3A shows that the nephrogenic zone width
(mean ± SD of five randomly selected cortical regions in each sample) in newborn kidneys from dams treated
with IL-6 was 358.4 ± 74.3 μm (n = 7) and significantly lower compared to control pups from mothers treated
with saline (453.9 ± 80.5 μm, n = 7; p = 0.039). Mature glomeruli and pre-tubular aggregates were counted over
5 separate regions using a 400 µm × 400 µm area grid. Figure 3B shows that the number of mature glomeruli
per grid in kidneys from pups exposed to maternal IL-6 (4.94 ± 0.76/grid, n = 7) was significantly higher compared to fetal kidneys from control pups born to dams given saline (3.23 ± 0.87/grid, n = 7, p = 0.002). Likewise,
maternal IL-6 also influenced the number of pre-tubular aggregates. Figure 3C shows that the number of pretubular aggregate/grid in kidneys from pups exposed to maternal IL-6 (6.00 ± 2.16/grid, n = 7) was significantly
higher compared to kidneys from control pups (2.71 ± 3.15/grid, n = 7, p = 0.041). Figure 3D shows results of
further histological evaluation that revealed increased mitotic karyorrhexis (a cell in mitosis while also undergoing the process of karyorrhexis) in pups gestationally exposed to increased maternal IL-6. The mean mitotic
karyorrhexis value was higher in pups exposed to IL-6 (51.29 ± 16.29 per grid, n = 7) compared to control pups
(38.43 ± 13.59 per grid, n = 7, p = 0.13).
Additionally, accelerated maturation at cellular level was evident from double immunostaining for podocytes
proteins podocalyxin and podocin as described previously to identify mature g lomeruli24. Podocytes are essential
for glomerular structure–function integrity and during development express podocalyxin early but podocin
later. Analysis for the number of mature glomeruli per 100× field following immunostaining for podocin and
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podocalyxin showed that the number of glomeruli expressing both podocalyxin and podocin was significantly
higher in kidneys from pups born to dams treated with IL-6 (25.30 ± 3.95/field, n = 2) compared to kidneys from
control pups born to dams given saline (11.92 ± 3.28/field, n = 2) (Fig. 4).
Overall, morphological examination from various aspects suggests that increased IL-6 accelerates kidney
development resulting in small kidneys under environmental stress of maternal inflammation that can have
lasting effects on kidney function in the offspring.

Cell cycle and apoptosis gene expression was altered in kidneys of newborns of mothers
treated with IL‑6 during gestation. The observed changes outlined above including accelerated matu-

ration, increased pre-tubular aggregates, and increased mitotic karyorrhexis led us to investigate the changes
in gene expression in cell cycle and apoptosis pathways in this model. Newborn kidneys from each dam were
pooled to obtain mRNA and 5–6 replicates for cell cycle and apoptosis were analyzed. Results of 96-well plate
RT2 Profiler PCR Arrays shown in Tables 1 and 2, and Supplementary Tables 2 and 3 include the fold-change and
p-values with brief description of their roles in mouse cell cycle pathway and mouse apoptosis pathway. Figure 5
shows how these differentially expressed genes are matched on the KEGG pathways. The Cell Cycle PCR Array
analysis showed that 47 (56.0%) of the 84 genes on the array plate were annotated in 123 genes in the KEGG Cell
Cycle (ko04110) pathway. Of the 19 genes differentially expressed in the PCR array plate, 14 genes were mapped
to the KEGG pathway. Thus, 29.8% (14/47) or 11.4% (14/123) genes were differentially expressed in the KEGG
Pathway. Results of the Apoptosis PCR Array analysis showed that 41 (48.8%) of the 84 genes on the array plate
were annotated in 136 genes in the KEGG Apoptosis (ko04210) pathway. Of the 18 genes differentially expressed
in the PCR array, 11 were mapped to the KEGG pathway. Thus, 26.8% (11/41) or 8.1% (11/136) genes were differentially expressed in the KEGG Pathway. While validation of genes of cell cycle and apoptosis is a part of our
future plans, these results are consistent with the interpretation that altered gene expression in these two pathways drives the observed accelerated maturation induced by elevated levels of IL-6 during gestation (Tables 1, 2,
Supplementary Tables 2, 3).

Gestational treatment of dams with IL‑6 resulted in increased total genomic DNA methylation
in the newborn kidney. Elevated levels of cytosine methylation correlate with more differentiated s tate25.

Newborn kidneys from each dam were pooled to obtain genomic DNA. IL-6 administration to mothers during gestation increased 5-methyldeoxycytosine (5mdC) in the newborn kidney (4.15 ± 0.046, n = 3) compared
to control (3.78 ± 0.057, n = 3, p < 0.05). Levels of 5-hydroxymethyldeoxycytosine (5hmdC) in the IL-6 exposed
fetal kidney (0.124 ± 0.013, n = 3) remained unchanged compared to control (0.125 ± 0.008, n = 3, p = NS). An
approximately 10% increase in methylated cytosine, but not hydroxymethylated cytosine, was detected in pups
born to IL-6 treated mothers.
Thus, gross and tissue morphometric analyses of glomerular and tubular development, immunofluorescence
analysis of podocyte specific protein, gene expression analysis for cell cycle and apoptosis, and mass spectrometric
analysis of methylated cytosine in DNA strengthen the idea that elevated maternal IL-6 induces a more differentiated state of the newborn kidney. These findings constitute the foundation of our plans to study newborns from
IL-6 treated mothers for increased susceptibility to kidney disease during adulthood.

Interleukin‑6 increased glomerular albumin permeability (Palb) in vitro. Previously, we have
shown that increased P
 alb indicates injury to the glomerular filtration barrier which precedes the onset of overt
proteinuria in a spectrum of kidney diseases26–29. Present results demonstrate a direct effect of IL-6 (0.01–5 ng/
mL) on Palb within 15 min of incubation. Figure 6 shows that IL-6 increased Palb in a dose-dependent manner.
A significant increase in Palb was noted at IL-6 concentration of 0.01 ng/mL, with maximal effect at 1 ng/mL
(p < 0.05). Pre-treatment with anti-IL-6 antibody completely blocked the increase in P
 alb using 1 ng/mL IL-6
(p < 0.05). These findings indicate a role for IL-6 in the glomerular filtration barrier wherein podocytes are considered critical for regulating the passage of plasma proteins into urine.
Interleukin‑6 disrupted the podocyte actin cytoskeleton in a dose‑dependent manner. A
dynamic actin cytoskeleton is critical for maintaining podocyte structure and function in the glomerular filtration barrier. Previously, we showed that injury to podocytes from puromycin, lipopolysaccharide or fluid flow
shear stress results in loss of fine F-actin stress fibers and appearance of thick bundles of cortical actin filaments
which are surrogate for condensation of the actin cytoskeleton seen in podocytes in vivo30,31. Rhodamine-conjugated phalloidin staining of podocytes incubated with IL-6 (0.001–1 ng/mL, 1 h) showed the formation of a
cortical ring indicating rearrangement of actin filaments. A more conspicuous finding was a dose-dependent
appearance of ‘actin dots’ (Fig. 7). Actin dots represent focal adhesions that suggest actin bundling next to the
plasma membrane. The cytoskeletal derangement seen in vitro serves as a useful surrogate for cellular changes
that would affect the filtration barrier function.
Podocytes express both sub‑units of IL‑6 receptor heterodimer and IL‑6 activates the Janus
kinase‑signal transducer and activator of transcription (JAK‑STAT) pathway. Podocytes are an

integral part of the glomerular filtration barrier and play pivotal role in maintaining the barrier to passage of
plasma proteins into glomerular filtrate. The IL-6 receptor is a heterodimer consisting of two transmembrane
glycoproteins, namely the ligand binding IL-6Rα (CD126) and gp130 (Il6st/gp130/IL6-β/CD130), the signaling subunit shared by several other cytokines of the IL-6 family. Expression of IL-6Rα and gp130 is limited to
certain cell types. To document if podocytes express both sub-units of IL-6 receptor heterodimer, we performed
gene expression studies in podocytes (n = 4) in duplicate using RT-qPCR with and without melting curve plots.
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◂Figure 3.  IL-6 injection to pregnant mice induces morphological changes in newborn kidneys. (A)

Representative image of newborn kidney from control dam treated with normal saline (left) and newborn
kidney from dam treated with IL-6 (10 pg/g intraperitoneally) starting in mid-gestation (middle). The box-plot
distribution of nephrogenic zone width is shown in the upper right panel (n = 7 in each group). The nephrogenic
zone width was significantly higher in control pups (p = 0.039). The second panel (B), third panel (C) and lower
panel (D) each shows a representative kidney tissue of a pup born to control dam (left) and to dam treated
with IL-6 (middle). The box-plot distribution of number of mature glomeruli, pretubular aggregate and mitotic
karyorrhexis measured per grid in a 400 µm × 400 µm grid over 5 separate areas is shown in the right panels
(n = 7 in each group). The number of mature glomeruli per grid (B) was significantly lower in control pups
(p = 0.002). The number of pretubular aggregates per grid was significantly lower in control pups (p = 0.041). The
number of cells showing mitotic karyorrhexis per grid was lower in control pups (p = 0.13).

The CT values (mean ± SEM) for IL-6Rα, gp130 and β-actin were 30.09 ± 0.09, 22.06 ± 0.11 and 17.87 ± 0.19,
respectively. RT-qPCR results showed a single peak on melting curve plot and subsequent RT-PCR showed a
single band on the agarose gel (Fig. 8A,B). The IL-6Rα and gp130 proteins were detectable by Western blotting
following immunoprecipitation (Fig. 8C).
Present results demonstrate that podocytes express IL-6 receptor heterodimer and respond to IL-6. Figure 9
shows Western Blot analysis for pJAK2, pSTAT3 and pSTAT5 following treatment of podocytes with 0.01, 0.1 and
1 ng/mL of IL-6 for 15 min. Increased phosphorylation of JAK2 (Tyr1007) and STAT3 (Tyr705) in podocytes was
observed. However, phosphorylation of STAT5 (Tyr694) was decreased following exposure to IL-6 highlighting
different functions of STAT isoforms.
Taken together, these in vitro results indicate that podocytes respond to IL-6 via its constitutively expressed
receptor resulting in JAK-STAT activation, cytoskeletal derangements, and subsequent impairment of the glomerular filtration barrier which is an early event in the onset of proteinuria seen with glomerular dysfunction
in CKD.

Discussion

Recent studies reporting low kidney volume/birth weight ratio, increased incidence of CKD, and increased risk
for congenital anomalies in children of obese mothers underscore the significance of intrauterine environment
and motivated us to develop this model to study susceptibility to CKD in adult p
 rogeny5–11. The results summarized above show that prenatal treatment of pregnant mice with IL-6 resulted in newborns with smaller kidneys,
lower body weight, kidney morphology indicating accelerated development, upregulated JAK-STAT pathway,
altered expression of cell-cycle and apoptosis genes, and increased genomic DNA methylation. Additionally, IL-6
increased albumin permeability of glomeruli ex vivo; deranged the actin cytoskeleton and upregulated JAK-STAT
pathway signaling in podocytes in vitro and attenuated the growth of metanephric kidney in vitro. We surmise
that elevated levels of IL-6 in chronic inflammation and/or exposure to increased maternal IL-6 during gestation
may contribute to greater susceptibility to CKD in the adult offspring.
IL-6 is a pleiotropic cytokine with diverse effects, and its elevated levels are routinely mentioned to signify
inflammation associated with pathophysiology of several conditions including CKD and obesity. However, the
effect of elevated maternal IL-6 on intrauterine development of the newborn kidney is unclear. Cytokines of the
IL-6 family are known to regulate a large number of cellular processes including development. Members of this
family include IL-6, Interleukin-11, Interleukin-27, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic
factor, cardiotrophin-1, novel neurotrophin-1/B cell stimulating factor-3 or cardiotrophin-like cytokine factor 1
(CLCF1), and neuropoietin. IL-6 is the most extensively studied member of this family of cytokines that primarily
activate the JAK-STAT pathway through a receptor complex composed of the transmembrane glycoprotein gp130
(signaling sub-unit) and a ligand-specific protein (ligand binding sub-unit). A third sub-unit protein may also
be present for engaging certain cytokines (e.g., CLCF1)32. A description of the nature and range of diverse and
sometimes opposite effects of IL-6 in different cell types and conditions is beyond the scope of this article but it
suffices to say that it engages cis and trans signaling mechanisms for mediating a large number of biological processes. Here we focused on the influence of elevated maternal IL-6 on the intrauterine development of the kidney.
Our plans for in vivo experiments using pregnant mice to study the effect of IL-6 on intrauterine development of kidneys were encouraged by previously reported observations in animals. These reports showed that
among various pro-inflammatory cytokines (IL-1β, TNFα, IL-6), only IL-6 crossed the placental barrier during
mid-gestation16–18. Additionally, mid-gestation injection of IL-6 resulted in progeny with hypertension during
adulthood16. Such molecular specificity of the placental barrier and long-term effect of IL-6 prompted us to
consider IL-6 as a unique surrogate to study effects of maternal systemic inflammation on kidney development.
Serum IL-6 levels reported in pregnant obese women are 1.5- to 2-fold higher compared to non-obese pregnant
women19–21. In our animal model we wanted to achieve serum levels of IL-6 similar to obese pregnant women.
Circulating levels of IL-6/mL are in the low picogram range. We also considered the rapid clearance of injected
IL-6 from circulation. Previous studies used 5 or 9 ng/g IL-6 for injection which were orders of magnitude higher
than circulating IL-6 in m
 ice16,18,33. We calculated that ~ 10 pg/g body weight would be sufficient to transiently
increase serum levels for IL-6 without prolonged increase in circulating levels. To keep IL-6 dosing to minimum,
it was injected at 48 h intervals. Serum IL-6 levels following intraperitoneal injection in mice at 10 pg/g body
weight achieved peak circulating levels at 1 h (~ 60 pg/mL) returning to baseline (~ 20 pg/mL) by 3 h (Multi-plex
Array, Bioplex-200, BioRad, Hercules, CA). Thus we refined and advanced the earlier approach by using lower
doses of IL-6 (IP,10 pg/g BWT or 1/500–1/900 of previously used amounts) every other day to timed-pregnant
mice starting on E12.516,18,33.
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Figure 4.  Double immunofluorescence staining with podocyte proteins podocalyxin and podocin showed
increased number of mature glomeruli in newborn kidneys. Immunofluorescence microscopy was performed
after double immuno-staining for podocyte proteins podocin (green) and podocalyxin (red). Representative
glomerular images (left panel at ×100 and right panel at ×400 magnifications) from newborn kidneys of salinetreated dams (Control) or IL-6 treated dams (10 pg/g, IP) starting in mid-gestation.
Figure 1 summarizes that prenatal treatment of dams with IL-6 resulted in newborns with lower weight,
smaller kidneys, and lower kidney weight/body weight ratio. These results are similar to findings described in
humans5. Body and kidney weights of pups exposed to IL-6 were lower by ~ 20% which is in accord with the
in vitro attenuation in the size of metanephroi treated with IL-6 (Fig. 1E). The tissue morphometry (Figs. 3, 4),
gene expression (Fig. 5) and DNA methylation in newborn kidney suggest potentially lasting effects of higher
levels of maternal IL-6. A consistent, reproducible, and convenient model is needed to investigate the specific
role of maternal inflammatory molecules. Current animal models using a high-fat Western diet are associated
with marked variability in weight, involve effects of small metabolites outside of inflammation, and tend to
breed poorly. IL-6, a pleiotropic cytokine, is highly suitable to model maternal systemic inflammation. This
experimental approach enables us to use very small amounts of IL-6 and successful completion of pregnancy in
all mice yielding sufficient number of animals for further study and allows for clear interpretation of results for
establishing causal relationship. In our animal model we have considered transplacental passage of IL-6, but we
need to also consider the independent role of placenta in our animal model.
Our previous work also suggests that intrauterine environmental stress influences the pace of development
and organ maturation for postnatal survival. For example, we detected significantly higher serum cortisol level
(stress marker) in human preterm neonates who did not develop respiratory d
 istress34. Dexamethasone, a synthetic glucocorticoid known to act like a stress hormone, is given to pregnant women at risk for premature
delivery to accelerate lung maturity for the preterm child’s survival. In animal models, dexamethasone not only
accelerates lung maturation but also results in decreased nephron number in rats, spiny mouse, and sheep35–38,
and poor response to salt loading or glucose tolerance test on long-term follow u
 p39,40. Thus, while intrauterine
environmental stress surrogate IL-6, accelerates organ development, it also appears to cause lower nephron
number as a trade-off as observed in present experiments. We did not measure serum cortisol in the pregnant
dams treated with saline or IL-6 in our current study.
Renal size and birth weight are often used as indicators of nephron endowment. Schreuder et al.41 reported
decrease in nephron number in natural intrauterine growth retardation (IUGR) or experimental IUGR by bilateral uterine artery ligation in their rat model. In line with observations of Schreuder et al.41, a 15–20% decrease
in kidney size observed in our experiments implies a lower nephron endowment. Similarly, in humans, birth
weight and kidney volume are well-recognized determinants of nephron number and overall kidney function in
health and disease. In humans, lower birth weight is associated with smaller kidney size and v olume42. Also, the
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FC

p value

G1 phase and
G1/S transition

S phase
and DNA
replication

G2 phase and
G2/M transition M phase

Cell cycle
checkpoint and
cell cycle arrest

Regulation of
the cell cycle

Gene

Description

Atm

Ataxia telangiectasia mutated
homolog

2.29

0.000073

Ccna1

Cyclin A1

1.93

0.000033

Cdc7

Cell division
cycle 7

1.78

0.002318

Chek1

Checkpoint
kinase 1
homolog

1.77

0.00677

Trp63

Transformation
related protein
63

1.73

0.000648

Skp2

S-phase kinaseassociated
protein 2 (p45)

1.59

0.001636

Cdk5rap1

CDK5 regulatory subunit
associated
protein 1

1.59

0.03108

Cell Cycle
Checkpoint
and Cell Cycle
Arrest

Chek2

CHK2 checkpoint homolog

1.54

0.004929

Cell Cycle
Checkpoint
and Cell Cycle
Arrest

Cdc6

Cell division
cycle 6 homolog

1.51

0.001708

Atr

Ataxia telangiectasia and rad3
related

1.46

0.000461

Cell Cycle CheckRegulation of the
point and Cell
Cell Cycle
Cycle Arrest

Ccna2

Cyclin A2

1.46

0.033909

Regulation of the
Cell Cycle

Ccnd2

Cyclin D2

1.42

0.000871

Regulation of the
Cell Cycle

Aurka

Aurora kinase A

1.4

0.012372

Regulation of
the Cell Cycle

Cdk1

Cyclin-dependent kinase 1

1.19

0.012966

Mki67

Antigen identified by monoclonal antibody
Ki 67

1.21

0.016439

Ccnd3

Cyclin D3

1.17

0.017355

Mcm2

Minichromosome maintenance deficient 2
mitotin

1.34

0.017567

Notch2

Notch gene
homolog 2

1.36

0.024446

Cell Cycle
Checkpoint and
Cell Cycle Arrest

Gadd45a

Growth arrest
and DNA-dam− 1.25
age-inducible 45
alpha

0.028246

Cell Cycle
Regulation of
Checkpoint and
the Cell Cycle
Cell Cycle Arrest

Negative
regulation of
cell cycle
Negative Regulation of Cell Cycle

Regulation of
the Cell Cycle

M Phase
S phase and
DNA Replication
Cell Cycle
Checkpoint
and Cell Cycle
Arrest

G2 Phase and
G2/M Transition

Negative Regulation of Cell Cycle
G1 Phase and
G1/S Transition

Regulation of
the Cell Cycle

S phase and
DNA Replication

Regulation of
the Cell Cycle

M Phase

M Phase

Cell Cycle
Regulation of
Checkpoint and
the Cell Cycle
Cell Cycle Arrest

S phase and
DNA Replication
Regulation of
the Cell Cycle
S phase and
DNA Replication

Table 1.  The genes with their role in phases of cell cycle and regulation of cell cycle, fold change (FC) and p
value performed on Qiagen’s RT2 Profiler PCR array gene expression analysis (mouse cell cycle panel PAMM020ZA) in kidneys from newborn exposed to increased maternal Interleukin-6 compared to control. The genes
with FC > 1.5 and p value < 0.05 are shown in bold, FC > 1.4 and p value < 0.05 are shown in italics and genes
with FC ≤ 1.4 and p value < 0.05 are shown in bold italics. The role of these genes in different phases of cell cycle
are also presented.

mean kidney parenchymal thickness is closely associated with kidney volume, and birth w
 eight43,44. Low birth
weight (or nephron endowment) is a key factor in the progression of CKD, ESRD, hypertension, albuminuria, and
cardiovascular disease in both adults and c hildren45–49. Meta-analysis of studies on low birthweight individuals
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Gene

Description

FC

p value

Tnfrsf11b

Tumor necrosis
factor receptor
superfamily,
member 11b
(osteoprotegerin)

2.03

0.000013

Trp63

Transformation
related protein 63

1.63

0.001611

Traf1

Tnf receptor-associated factor 1

1.56

0.000064

Atf5

Activating transcription factor 5

1.54

0.000052

Il10

Interleukin 10

− 1.76

0.003926

Fasl

Fas ligand (TNF
superfamily, member 6)

Bcl2l10

Bcl2-like 10

Xiap

Induction of
apoptosis

Anti-apoptotic

Death domain
proteins/DNA
damage

Caspases

Positive
regulation

Negative
regulation

Death Domain
Proteins
Induction of
Apoptosis

Anti-Apoptotic

DNA Damage
Positive Regulation

Anti-Apoptotic
Anti-Apoptotic
Induction of
Apoptosis

Positive Regulation

1.47

0.006512

− 1.38

0.000557

Anti-Apoptotic

Caspase Activators

Negative Regulation

X-linked inhibitor
of apoptosis

1.4

0.00135

Anti-Apoptotic

Caspase Inhibitors

Negative Regulation

Traf2

Tnf receptor-associated factor 2

1.22

0.004307

Pycard

PYD and CARD
domain containing

1.35

0.004527

Induction of
Apoptosis

Caspases/Caspase
Activators

Positive Regulation

Casp4

Caspase 4, apoptosis-related cysteine − 1.27
peptidase

0.006693

Induction of
Apoptosis

Caspases

Positive Regulation

Dffa

DNA fragmentation factor, alpha
subunit

1.26

0.016719

Induction of
Apoptosis

Fadd

Fas (TNFRSF6)associated via
death domain

1.27

0.024924

Induction of
Apoptosis

Bid

BH3 interacting
domain death
agonist

1.32

0.026291

Induction of
Apoptosis

Diablo

Diablo homolog
(Drosophila)

1.15

0.026748

Induction of
Apoptosis

Gadd45a

Growth arrest and
DNA-damageinducible 45 alpha

− 1.22

0.027658

Ripk1

Receptor
(TNFRSF)-interacting serine-threonine kinase 1

1.21

0.039765

Mapk1

Mitogen-activated
protein kinase 1

1.16

0.0467

Positive Regulation

Negative Regulation
Death Domain
Proteins

Positive Regulation
Positive Regulation

Positive Regulation
Death Domain
Proteins
Induction of
Apoptosis

Table 2.  The genes with their role in apoptosis, fold change (FC) and p value performed on Qiagen’s R
 T2
Profiler PCR Array Gene Expression Analysis (Mouse Apoptosis Panel PAMM-012ZA) in kidneys from
newborns exposed to increased maternal Interleukin-6 compared to control dams. The genes with FC > 1.5 and
p value < 0.05 are shown in bold, FC > 1.4 and p value < 0.05 are shown in italics and genes with FC ≤ 1.4 and p
value < 0.05 are shown in bold italics. The role of these genes in apoptosis are also presented.

reported 81%, 58%, 79% and 21% increased risk for albuminuria, ESRD, CKD and hypertension, respectively50–52.
Thus, low birthweight increases the susceptibility to CKD. Thus, low birthweight and low kidney weight with
accelerated maturation observed in present studies leads us to postulate that newborns from dams treated with
IL-6 will be suitable to study susceptibility to CKD later in life.
CKD is associated with glomerular dysfunction resulting in albuminuria/proteinuria22,23, therefore, we also
tested the direct effect of IL-6 on the glomerular filtration barrier function. Our results provide evidence for a
direct effect of IL-6 on glomerular filtration barrier (Fig. 6), upregulation of JAK-STAT signaling in podocytes
(Fig. 9) and derangement of actin cytoskeleton in podocytes (Fig. 7). Podocytes are a key constituent of the
glomerulus and their ultra-structural integrity is essential for the glomerular filtration barrier function that
regulates passage of plasma proteins into urine. Interdigitating foot processes from podocytes cover the basement
membrane over the capillary endothelial cells and form slit pore junctions essential for regulating the passage
of plasma proteins. An elaborate and dynamic actin cytoskeleton is critical for maintaining the characteristic
cell body and foot processes that maintain the function of podocytes. Derangement of the actin cytoskeleton by
IL-6 (Fig. 7) is comparable to that caused by other agents. We have previously shown that puromycin, lipopolysaccharide, prostaglandin E
 2 or fluid flow shear stress induce loss of fine F-actin stress fibers and appearance
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Figure 5.  JAK-STAT, cell cycle and apoptosis pathways (KEGG pathways). JAK-STAT pathway plays a role in
cell cycle and apoptosis. Genes with significantly different expression were identified using specific R
 T2 Profiler
PCR Arrays for cell cycle and apoptosis. Of these, 14 (11.4% of 123 genes) of cell cycle gens and 11 (8.1% of
136 genes) of apoptosis genes were mapped to KEGG pathways (adapted with permission from Kanehisa
Laboratories (KEGG Database Project)88,89). Mapped genes are highlighted in red font.
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Figure 6.  IL-6 increases glomerular albumin permeability (Palb) in vitro. Isolated rat glomeruli were incubated
with IL-6 alone or after pretreatment with anti-IL-6 antibody for 15 min at 37 °C followed by video microscopy,
determination of glomerular volume change and calculation of Palb. (A) IL-6 (0.01–5 ng/mL) caused significant
dose-dependent increase in Palb at 0.1–1 ng/mL (*p < 0.05 vs. control) with no further increase in IL-6 between
1 and 5 ng/mL. (B) Pretreatment of glomeruli with anti-IL-6 antibody (150 µg/mL) followed by addition of IL-6
(1 ng/mL) blocked the effect of IL-6 (*p < 0.05 vs. IL-6 1 ng/mL). Values are means ± SE of P
 alb determinations in
20 glomeruli from 4 rats (5 glomeruli/rat n = 4 rats).

Figure 7.  IL-6 causes derangement of the actin cytoskeleton in cultured mouse podocytes. Differentiated
podocytes were incubated with IL-6 (0.001–1 ng/mL) for 1 h at 37 °C. Cells were stained for actin filaments
using Rhodamine-conjugated phalloidin and observed using confocal microscope. Representative images
(×63 objective) show a parallel arrangement of F-actin thick bundles running across the cell in control
podocytes. IL-6 (0.001–1 ng/mL) caused change in the thickness, length, and arrangement of actin filaments in a
dose-dependent manner. These changes were discernible at 0.001 ng/mL IL-6. A dose-dependent appearance of
‘actin dots’ representing focal adhesions and actin bundling next to the plasma membrane was conspicuous.

Figure 8.  Cultured podocytes express IL-6 receptor sub-units IL-6Rα and gp130. Monolayers of immortalized
murine podocytes were used to prepare cell lysate for total RNA and protein expression of IL-6Rα and gp130 as
described. (A) Melting curve plot using RT-qPCR showed single peaks for IL-6Rα and gp130 each. (B) RT-PCR
analysis showed single band on 1% agarose gels for IL-6Rα and gp130 each (n = 4 each sample analyzed in
duplicates). Western blotting for IL6Rα and gp130 was performed following immunoprecipitation using 1 mg
total protein IL-6Rα and 0.5 mg for gp130 (no protein for control). (C) Western blot image shows a band at 80
kD demonstrating expression of IL-6Rα and at 130 kD for gp130 in podocytes. Total protein loaded 5, 10, 15,
20 and 23 µg of protein lysate for gp130 expression in the gel. These studies demonstrate both gene and protein
expression of IL-6Rα and gp130 in podocytes.
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Figure 9.  Treatment of podocytes with IL-6 results in upregulation of JAK-STAT pathway. Representative
Western blot (n = 4) showing changes in phosphorylation of JAK2, STAT3 and STAT5 in mouse podocytes
treated with IL-6 (0.01–1 ng/mL) for 15 min. β-Actin was used as the loading control. The bar graphs show the
changes in pJAK2, pSTAT3 and pSTAT5 across the four replicates (*p < 0.05).
of thick bundles of cortical actin filaments in p
 odocytes30,31. Changes in the podocyte cytoskeleton observed
in vitro serve as indicators of impaired filtration barrier function assessed using the albumin permeability (Palb)
assay using intact glomeruli.
The Palb assay evaluates integrity of the glomerular filtration barrier function in vitro. As shown in Fig. 6,
IL-6-induced increase of P
 alb that was blocked by anti-IL-6 antibody suggesting a direct effect of IL-6 on the
filtration barrier corroborating its effect on podocytes. Previously, we and others have used the P
 alb assay to
show the direct effects of cytokines (TNFα, TGFβ1, CLCF1), free radicals, eicosanoids, and other agents on the
glomerular filtration barrier function. Using rodent models of proteinuric kidney disease we have demonstrated
that increased Palb indicates injury to the glomerular filtration barrier preceding the onset of overt proteinuria26–29.
Thus, the observed effect of IL-6 on podocyte structure indicates its effect on the glomerular filtration barrier.
The in vitro effects of IL-6 on podocytes and Palb strongly also relate to our ongoing work on CLCF1, a member of the IL-6 family of cytokines, that also utilizes gp130 subunit in a tripartite receptor complex and activates
the JAK-STAT signaling pathway. We identified CLCF1 in sera from patients with recurrent focal segmental
glomerulosclerosis (FSGS)53. Treatment with CLCF1 increased P
 alb of isolated rat glomeruli that was blocked
by anti-CLCF1 antibody or by JAK2 inhibitor B
 MS91154354,55. Moreover, CLCF1 caused derangement of the
actin cytoskeleton organization, upregulated phosphorylated JAK2 and STAT3 in cultured p
 odocytes54–56. A
single injection or chronic infusion of CLCF1 for 28 days increased pSTAT3 in the renal cortex and induced
albuminuria55. Similarly, present studies demonstrated upregulation of pJAK2 and pSTAT3 in podocytes and in
kidneys exposed to IL-6 (Figs. 2, 9). These parallel observations using CLCF1, and IL-6 further strengthen the
significance of the JAK-STAT pathway in CKD.
Research on JAK-STAT signaling in CKD has intensified in recent years. JAK-STAT pathway is upregulated in
early diabetic nephropathy in animal models and in human kidney t issue57,58. Glomerular and tubulointerstitial
expression of JAK and STAT is increased, and JAK2 inhibitors mitigate diabetic kidney i njury58–60. In addition
to diabetic nephropathy, an activated JAK-STAT pathway has been reported in UUO, in HIVAN, in nephrotic
syndrome, in ADPKD and in IgA g lomerulonephritis61–67. Thus, upregulation of the JAK-STAT pathway is
apparent in CKD of different etiologies.
We believe that there are at least two clinical scenarios where susceptibility for CKD needs special attention as the reason(s) for progression to ESRD in these conditions is still unclear: (a) in adults following kidney
donation and (b) in children born with solitary functioning kidney. We recently reviewed the accumulating
evidence that living kidney donation increases the risk of ESRD in donors despite stringent screening68. The
risk for ESRD in donors compared to eligible healthy individuals increases 6.5-fold (USA), 11.4-fold (Norway),
and 3.5- to 5.5-fold (Canada), with an overall 8.3-fold increase reported in a meta-analysis of 52 s tudies69–72.
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There is a cumulative increase in the incidence of ESRD over time post-kidney donation with a reported mean
interval of 27.1 ± 9.8 years73–75. Similarly, nearly 50% children born with SFK progress to ESRD as young adults76.
Children with SFK manifest renal injury at a median age of ~ 15 years; 16–26% develop hypertension, 19–21%
have proteinuria, and 6–10% have eGFR < 60 mL/min/1.73 m
 277–79.
In a paradigm for developmental origins of health and disease (Barker’s hypothesis), maternal systemic
inflammation may be a critical factor in the developing kidney and results in altered fetal programming which
becomes consequential in those who develop CKD/ESRD following stress or injury later in life. We envision a
‘two-hit model’ to address the susceptibility to CKD in adults. Our proposed mouse model will be valuable for
correlating the intrauterine insult (‘first hit’) with a ‘second hit’ such as dietary stress, unilateral nephrectomy,
diabetes, and immune injury that results in the development of adult CKD. As noted above, overactivation of the
JAK-STAT pathway observed during development in these studies, and its relevance in kidney diseases of different etiologies in adults is highly significant for future translational studies and for developing intervention(s).
In conclusion, present studies provide a mouse model to further investigate the effects of prenatal exposure
to IL-6 as a surrogate of maternal systemic inflammation (e.g., maternal obesity) that results in offspring with
small kidneys with accelerated maturation, and JAK-STAT activation. We intend to use this model to study
susceptibility to CKD in adult offspring. Such models will prove highly valuable for determining the long-term
effects of the growing incidence of maternal obesity, childhood obesity and increased prevalence of obesity and
CKD across the globe.

Material and methods

Prenatal treatment of pregnant mice with IL‑6.

Animal studies were approved by the Institutional
Animal Care and Use Committee (IACUC), Institutional Biosafety Committee/ Subcommittee on Research
Safety (IBC/SRS) and the Research and Development (R&D) Committee at the VA Medical Center, Kansas City,
MO, USA. The study was carried out in compliance with the ARRIVE guidelines. All methods were performed
in accordance with the relevant guidelines and regulations. Timed-pregnant C57BL/6 mice were obtained from
Charles River Laboratories (Indianapolis, IN) and maintained at AAALAC-approved facilities with unrestricted
access to food and water under light/dark cycles of 12/12 h. Pregnant mice in the experimental group received
IL-6 (10 pg/g body weight [BW]) intra-peritoneally (IP) on alternate days from E12.5 to end of gestation while
the control pregnant mice received normal saline. The pups were sacrificed within 6 h of birth and studied on
postnatal day P0. Following euthanasia, newborn kidneys were removed by dissection and fixed in 10% formalin, embedded in optimal cutting temperature compound (OCT), or used to isolate total RNA and to prepare
total protein lysate. Newborn kidney samples were handled independently or pooled together from a single dam
depending on the design of the experiment.

Light microscopy observation of newborn mouse kidney morphology to identify effects of IL‑6
on kidney development. Five micrometer thick sections of formalin-fixed kidneys embedded in paraffin

blocks were obtained and stained with hematoxylin and eosin. Kidney tissue sections from 1–2 representative
animals from saline (n = 4) or IL-6 treated (n = 4) dams were used for assessing morphology, nephrogenic zone
width, mature glomeruli, and pre-tubular aggregates. The nephrogenic zone was defined as the area in the outer
renal cortex exhibiting developing nephrons in the form of comma and S-shaped bodies. Kidney sections were
viewed at 200× magnification and analyzed using Image J software suite (National Institute of Health and the
Laboratory for Optical and Computational Instrumentation at the University of Wisconsin, Madison WI) for
measurement of the nephrogenic zone width. Average width for the nephrogenic zone was calculated from five
separate randomly measured regions80,81. The developing kidney shows glomeruli at different stages of development from comma, S-shape, immature, and mature glomeruli. In developing kidney cap mesenchymal cells
aggregate and condense to form a ball of cells near the tip of ureteric bud to form pre-tubular aggregates that may
eventually form a mature tubule. A 400 µm × 400 µm grid was used over five separate areas to count the number
of mature glomeruli and pre-tubular aggregates per grid.

Double immunofluorescence staining for podocyte proteins podocin and podocalyxin in new‑
born mouse kidney glomeruli as indicators of maturation. Four micrometer thick sections of OCT

embedded kidneys were double immune stained for podocin and podocalyxin to identify mature glomeruli as
described previously24. We used rabbit anti-podocin antibody (Catalog # ab50339, Abcam, Cambridge, MA,
USA) at 1:500 and goat anti-podocalyxin antibody (Catalog #AF1556, R&D Systems, Minneapolis, MN, USA) at
1:200 with secondary antibodies (at 1:500 dilution) Alexa fluor 488 donkey anti-rabbit (Catalog # A21206) and
Alexa Fluor plus 594 Donkey anti-goat (Catalog # A32758) from Invitrogen, Waltham, MA, USA. The number
of mature glomeruli expressing both podocalyxin and podocin were counted at 100× from five separate images
per animal.

In vitro organotypic culture to observe the effect of IL‑6 on developing metanephroi. Metanephroi

were harvested from pregnant dams at post-conception day 13.5 and grown in vitro in medium containing
10 pg/mL IL-6 or without IL-6 (Control) for up to 72 h. Organ cultures were replenished with fresh treatment
medium every 24 h. Morphology of metanephric kidneys cultures was photographed at 0, 24, 48 and 72 h using
light microscopy at identical magnifications. Metanephroi were outlined manually, and the surface area was
calculated by pixel counting. Net growth was determined as the mean percent change in the surface area from
before treatment (baseline) to the surface area after treatment. Image J software was used for quantification as
described82.
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Total RNA isolation, quantitative real time RT‑PCR (RT‑qPCR) and RT‑PCR to evaluate gene
expression in podocyte and kidney tissue. Total RNA from podocytes and newborn kidneys was

extracted using the Mini Total RNA Purification System from Qiagen (Qiagen, Germantown, MD) Catalog#74104 performed using on-column DNase digestion step. The RNA preparation was then analyzed for quality
and quantity by absorbance at 260 and 280 nm using Nanodrop for Nucleic Acid Quantification (Thermo Fisher
Scientific, Waltham, MA, USA). The OD260:OD280 absorbance ratio was 1.8–2.0 indicating clean RNA preparations. RNA was aliquoted and stored at − 80 °C. RT-PCR was performed using commercially available primers
for IL-6Rα (CD126) Catalog# PPM03027F-200, gp130 (Il6st/gp130/IL6-β/CD130) Catalog# PPM03123C-200
and β-actin (Actb) Catalog# PPM02945B-200 from Qiagen (Qiagen, Germantown, MD, USA). The predicted
PCR products were 108, 97 and 154 bp for IL-6Rα, gp130 and β-actin, respectively. The PCR product following
RT-PCR was electrophoresed using 1% agarose gel to confirm the size and for single product only.

PCR Array analysis of cell cycle and apoptosis related genes to determine effect of IL‑6 on
specific gene expression. Cell cycle and apoptosis pathway genes were evaluated using specific 96-well

plate RT2 Profiler PCR Arrays from Qiagen (Qiagen, Germantown, MD, USA). Mouse cell cycle (PAMM020ZA, Qiagen) and mouse apoptosis (PAMM-012Z, Qiagen) panels were used to design these arrays. The
RT2 Profiler PCR Array included controls for genomic DNA contamination, reverse transcription efficiency,
real-time PCR efficiency and housekeeping genes β-glucuronidase (Gusb), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), β-actin (Actb), heat shock protein 90 alpha (cytosolic), class B member (Hsp90ab1) and β-2
microglobulin (B2m). One µg of total RNA was converted to cDNA using Qiagen R
 T2 first strand kit (Qiagen,
Catalog# 330404). RT-qPCR analysis of Qiagen RT2 Profiler PCR Array was performed using SYBR green with
Rox according to the manufacturer’s instructions. All raw data were uploaded to Qiagen data analysis website
(https://geneglobe.qiagen.com). Samples from five separate experiments were analyzed.

Liquid chromatography‑mass spectrometry (LC–MS) analysis of total DNA methylation to
determine potential epigenetic effects of IL‑6. Global DNA methylation studies, a marker of epi-

genetic changes in fetal DNA, were performed using LC–MS at Zymo Research Corporation (Irvine, CA,
USA). Briefly, the newborn kidney tissue was cut into small pieces and sonicated for DNA isolation and analysis. Samples of genomic DNA from each group were hydrolyzed using DNA Degradase Plus Cocktail (Zymo
Research). Nucleotides were separated using reverse phase liquid chromatography (UPLC column Eclipse C18,
2.1 × 50 mm, 1.8 um particles, Agilent). The effluent was directed to an ESI source (Agilent Jet Stream) connected
to a quadrupole mass spectrometry system (Agilent 6460 QQQ). Each sample was analyzed in triplicates.

Glomerular albumin permeability (Palb) assay in vitro to determine a direct effect of IL‑6 on
glomerular filtration barrier. Freshly isolated glomeruli from male Sprague Dawley (200–250 g) rats were

used to study the changes in glomerular filtration barrier function characteristics using an in vitro assay established in our laboratory. Briefly, kidneys were harvested from rats and renal cortex was cut into approximately
1 mm pieces and pressed through 80-mesh stainless screen followed by passing the filtrate through 120 and 200
mesh screens sequentially. Glomeruli were recovered from atop the 200-mesh screen at room temperature in a
physiological buffer solution (pH 7.4) containing 5 gm/dL bovine serum albumin (BSA).
Isolated glomeruli were incubated with the test substance in medium containing 5% BSA for 15 min at 37 °C,
transferred to glass coverslips coated with poly-l-lysine (Sigma-Aldrich) and observed using video microscopy.
Glomerular images were recorded in the initial incubation medium (5 gm/dL BSA) and 1 min after switching
to lower oncotic (1 gm/dL BSA) medium. Oncotic gradient across the capillary wall (5% BSA in the lumen vs.
1% in the bathing medium) results in a net fluid influx causing an increase in glomerular volume. Change in
glomerular volume (ΔV) due to oncotic gradient calculated from the average of 4 diameters of the video image
(ΔV = (Vfinal − Vinitial)/Vinitial ×100%) and is directly related to the oncotic gradient (ΔΠ) across the capillary wall.
Reflection coefficient (σalb) was calculated (σalb = ΔVexperimental/ΔVcontrol). Convectional permeability to albumin
(Palb) is defined as (1-σalb) and describes the movement of albumin consequent to water flow on a unit less scale
of 0–1. When σalb is zero, albumin moves at the same rate as water and P
 alb is 1.0 indicating damage to the filtration barrier; when σalb is 1.0, albumin does cross the membrane with water and P
 alb is zero indicating an intact
barrier26,83.

Podocyte cell culture. Conditionally immortalized mouse podocytes containing thermosensitive tsA58
mutant T-antigen (kindly provided by Dr. Peter Mundel) were seeded on collagen-I coated 25 c m2 polystyrene flasks and first propagated in RPMI 1640 containing l-glutamine, 10% fetal bovine serum, 100 units/mL
penicillin and 0.1 mg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) supplemented with 10 units/mL of
γ-interferon (Cell Sciences, Norwood, MA) under permissive conditions at 33 °C with 95% humidity and 5%
CO284. Cells were then transferred to non-permissive conditions (37 °C without γ-interferon) to induce differentiation. Differentiated podocytes on day 14 were used for experiments outlined below.
Confocal microscopy to determine IL‑6‑induced changes in the actin cytoskeleton in podo‑
cytes. Podocytes grown on Collagen-I coated coverslips were incubated with 0.001–1 ng/mL IL-6 for 1 h.

Cells were washed with PBS (× 2), fixed in 4% paraformaldehyde for 10 min and then incubated with phalloidin
conjugated Alexa Fluor 568 dye (1:200 dilution, Invitrogen, Carlsbad, CA) for 30 min in the dark. Cover slips
were mounted in 5% n-propyl gallate in buffered glycerol (glycerol:PBS, 9:1). Cells were viewed using a Leica
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confocal microscope (Leica DMI 4000 B) at 561 nm excitation. Laser intensity, gain settings, scaling, individual
section depth, and pinhole settings were constant throughout.

Western blotting to determine protein expression in podocytes and kidney tissue. Cultured

podocytes and newborn kidneys were lysed in RIPA buffer containing protease and phosphatase inhibitors.
Total protein was quantitated using a bicinchoninic acid protein assay kit (BCA1, Sigma-Aldrich, St. Louis, MO).
Immunoprecipitation was carried out by mixing 2 µg antibodies IL-6Rα (SC-374259, Santa Cruz Biotechnology,
Dallas, TX) or gp130 (SC-376280, Santa Cruz Biotechnology, Dallas, TX) with 75 µL/mL of Protein G Sepharose beads (2 mg/mL, P3296, Sigma-Aldrich, St. Louis, MO, USA) for 1 h. Centrifuged beads were washed and
incubated with 1 mg aliquot of protein lysate for IL-6Rα, 0.5 mg for gp130 and 0 mg (negative control) overnight
at 4 °C. Protein bound agarose beads were washed with PBS and resuspended in sample buffer and 20 µL and
used for Western blotting as described p
 reviously85–87. Briefly, proteins were denatured in the sample buffer
containing β-mercaptoethanol at 94 °C for 5 min. For other Western blots, total protein (10–20 µg/lane) was
electrophoresed in 10% Tris–Glycine gel using SDS-PAGE and transferred to a PVDF membrane, washed with
TBST (0.1% Tween-20), and blocked using 5% non-fat milk powder. Antibodies to the following proteins were
obtained from Cell Signaling Technology (CST), Danvers, MA, and used at 1:1000 dilution: p-JAK2 (CST catalog# 4406S), p-STAT3 (CST# 9145S) and p-STAT5 (CST# 9359S). β-Actin (Catalog #A5441, Sigma, St. Louis,
MO) was used as the loading control. TBST-washed membrane was incubated with HRP-conjugated secondary
antibody to each primary antibody. Chemiluminescence reagent (Pierce, Rockford, IL) was added and chemiluminescence was detected using iBright FL100 imaging system (Invitrogen, Waltham, MA, USA). Images were
analyzed using Image J program. Samples from 4 replicates for each experimental treatment were analyzed.

Statistics. We used GraphPad and SPSS 23 statistical software for two group comparisons and graphs. In
most of the experiments we had pooled newborn kidneys from a litter as n = 1, but as the effect of the offspring of
one litter is statistical dependent among each other, all offspring of one litter were counted as n = 1 and analyzed
again for certain analyses. Unpaired t-test on GraphPad was used for two group comparisons. A p value < 0.05
was considered significant. For Qiagen RT2 Profiler PCR Array data analysis, raw data were uploaded to the
Qiagen data analysis website (https://geneglobe.qiagen.com), which selects one or more of its five housekeeping
genes in the RT2 Profiler PCR Array. It then calculates fold-change as the normalized gene expression 2 (−∆∆CT)
values in the test sample divided by the normalized gene expression 2(−∆∆CT) values in the control sample. A foldchange values greater than one indicates a positive- or an up-regulation, and values less than one indicate a negative or down-regulation. The p values are calculated based on a Student’s t test of the replicate 2 (−∆∆CT) values for
each gene in the control group and treatment groups. The p value calculation is based on parametric, unpaired,
two-sample equal variance and two-tailed distribution.

Received: 11 March 2021; Accepted: 15 June 2021

References

1. Stenvinkel, P. et al. IL-10, IL-6, and TNFalpha: Central factors in the altered cytokine network of Uremia—the good, the bad, and
the ugly. Kidney Int 67, 1216–1233 (2005).
2. Barreto, D. V. et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients
with chronic kidney disease. Kidney Int. 77, 550–556 (2010).
3. Roytblat, L. et al. Interleukin-6 levels in obese patients. Obes. Res. 8, 673–675 (2000).
4. Eder, K., Baffy, N., Falus, A. & Fulop, A. K. The major inflammatory mediator interleukin-6 and obesity. Inflamm. Res. 58, 727–736
(2009).
5. Lee, Y. Q. et al. The relationship between maternal adiposity during pregnancy and fetal kidney development and kidney function
in infants: The Gomeroi gaaynggal study. Physiol. Rep. 7, e14227 (2019).
6. Macumber, I., Schwartz, S. & Leca, N. Maternal obesity is associated with congenital anomalies of the kidney and urinary tract in
offspring. Pediatr. Nephrol. 32, 635–642 (2017).
7. Honein, M. A., Moore, C. A. & Watkins, M. L. Subfertility and prepregnancy overweight/obesity: Possible interaction between
these risk factors in the etiology of congenital renal anomalies. Birth Defects Res. A Clin. Mol. Teratol. 67, 572–577 (2003).
8. Filler, G. et al. Should prevention of chronic kidney disease start before pregnancy?. Int. Urol. Nephrol. 40, 483–488 (2008).
9. Blomberg, M. I. & Källén, B. Maternal obesity, and morbid obesity: The risk for birth defects in the offspring. Birth Defects Res. A
Clin. Mol. Teratol. 88, 35–40 (2010).
10. Hsu, C. W., Yamamoto, K. T., Henry, R. K., De Roos, A. J. & Flynn, J. T. Prenatal risk factors for childhood CKD. J. Am. Soc. Nephrol.
25, 2105–2111 (2014).
11. Ross, W. R. & McGill, J. B. Epidemiology of obesity and chronic kidney disease. Adv. Chronic Kidney Dis. 13, 325–335 (2006).
12. Boubred, F. et al. Developmental origins of chronic renal disease: An integrative hypothesis. Int. J. Nephrol. 2013, 346067 (2013).
13. Nenov, V. D., Taal, M. W., Sakharova, O. V. & Brenner, B. M. Multi-hit nature of chronic renal disease. Curr. Opin. Nephrol. Hypertens. 9, 85–97 (2000).
14. Schreuder, M., Delemarre-van de Waal, H. & van Wijk, A. Consequences of intrauterine growth restriction for the kidney. Kidney
Blood Press. Res. 29, 108–125 (2006).
15. Burton, G. J. & Fowden, A. L. The placenta: A multifaceted, transient organ. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140066
(2015).
16. Samuelsson, A. M. et al. A Prenatal exposure to interleukin-6 results in hypertension and increased hypothalamic–pituitary–adrenal
axis activity in adult rats. Endocrinology 145, 4897–4911 (2004).
17. Buhimschi, C. S. et al. Fetal inflammatory response in women with proteomic biomarkers characteristic of intra-amniotic inflammation and preterm birth. Br. J. Obs. Gyn. 16, 257–267 (2009).

Scientific Reports |
Vol:.(1234567890)

(2021) 11:13260 |

https://doi.org/10.1038/s41598-021-92751-6

16

www.nature.com/scientificreports/
18. Dahlgren, J., Samuelsson, A. M., Jansson, T. & Holmäng, A. Interleukin-6 in the maternal circulation reaches the rat fetus in midgestation. Pediatr. Res. 60, 147–151 (2006).
19. Ramsay, J. E. et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J. Clin.
Endocrinol. Metab. 87, 4231–4237 (2002).
20. Stewart, F. M. et al. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function
throughout pregnancy in lean and obese mothers. J. Clin. Endocrinol. Metab. 92, 969–975 (2007).
21. Roberts, K. A. et al. Placental structure, and inflammation in pregnancies associated with obesity. Placenta 32, 247–254 (2011).
22. Coresh, J. et al. Change in albuminuria and subsequent risk of end-stage kidney disease: An individual participant-level consortium
meta-analysis of observational studies. Lancet Diabetes Endocrinol. 7, 115–127 (2019).
23. Carrero, J. J. et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int.
91, 244–251 (2017).
24. Refaeli, I. et al. Distinct functional requirements for podocalyxin in immature and mature podocytes reveal mechanisms of human
kidney disease. Sci. Rep. 10, 9419 (2020).
25. Niller, H. H., Demcsák, A. & Minarovits, J. DNA methylation in eukaryotes: Regulation and function. In Cellular Ecophysiology
of Microbe. Handbook of Hydrocarbon and Lipid Microbiology (ed. Krell, T.) 509–570 (Springer, 2007).
26. Sharma, M., Sharma, R., McCarthy, E. T. & Savin, V. J. The focal segmental glomerulosclerosis permeability factor: Biochemical
characteristics and biological effects. Exp. Biol. Med. 229, 85–98 (2004).
27. Rangel-Filho, A. et al. Rab38 is the RF-2 gene and it modulates proteinuria and albuminuria independently of changes in glomerular
permeability in the Fawn Hooded hypertensive rat. J. Am. Soc. Nephrol. 16, 852–856 (2005).
28. Savin, V. J. et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental
glomerulosclerosis. N. Engl. J. Med. 334, 878–883 (1996).
29. Sharma, M. et al. Arachidonic acid metabolites mediate the radiation-induced increase in glomerular albumin permeability. Exp.
Biol. Med. 231, 99–106 (2006).
30. Srivastava, T. et al. Prostaglandin E(2) is crucial in the response of podocytes to fluid flow shear stress. J. Cell Commun. Signal 4,
79–90 (2010).
31. Srivastava, T. et al. LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: Changes in TLR profile.
J. Cell Commun. Signal 7, 49–60 (2013).
32. Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem. J. 374, 1–20 (2003).
33. Smith, S. E., Li, J., Garbett, K., Mirnics, K. & Patterson, P. H. Maternal immune activation alters fetal brain development through
interleukin-6. J. Neurosci. 27, 10695–10702 (2007).
34. Srivastava, T., Merchant, R. H. & Ambadekar, M. C. Cord blood cortisol levels and respiratory distress syndrome. Indian Pediatr.
31, 923–928 (1994).
35. Ortiz, L. A., Quan, A., Weinberg, A. & Baum, M. Effect of prenatal dexamethasone on rat renal development. Kidney Int. 59,
1663–1669 (2001).
36. Singh, R. R. et al. Prenatal corticosterone exposure results in altered AT1/AT2, nephron deficit and hypertension in the rat offspring.
J. Physiol. 579, 503–513 (2007).
37. Dickinson, H., Walker, D. W., Wintour, E. M. & Moritz, K. Maternal dexamethasone treatment at midgestation reduces nephron
number and alters renal gene expression in the fetal spiny mouse. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R453–R461
(2007).
38. Celsi, G. et al. Prenatal dexamethasone causes oligonephronia, sodium retention, and higher blood pressure in the offspring.
Pediatr. Res. 44, 317–322 (1998).
39. Moritz, K. M. et al. Prenatal glucocorticoid exposure in the sheep alters renal development in utero: Implications for adult renal
function and blood pressure control. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R500–R509 (2011).
40. Wintour, E. M. et al. Reduced nephron number in adult sheep, hypertensive as a result of prenatal glucocorticoid treatment. J.
Physiol. 549, 929–935 (2003).
41. Schreuder, M. F. et al. Glomerular number and function are influenced by spontaneous and induced low birth weight in rats. J.
Am. Soc. Nephrol. 16, 2913–2919 (2005).
42. Simonetti, G. D. et al. Salt sensitivity of children with low birth weight. Hypertension 52, 625–630 (2008).
43. Brennan, S. & Kandasamy, Y. Renal parenchymal thickness as a measure of renal growth in low-birth-weight infants versus normalbirth-weight infants. Ultrasound Med. Biol. 39, 2315–2320 (2013).
44. Diehm, C. J. et al. Assessment of fetal kidney growth and birth weight in an indigenous Australian cohort. Front. Physiol. 8, 1129
(2018).
45. Keller, G., Zimmer, G., Mall, G., Ritz, E. & Amann, K. Nephron number in patients with primary hypertension. N. Engl. J. Med.
20, 101–108 (2003).
46. Al Salmi, I. et al. Birth weight and stages of CKD: A case-control study in an Australian population. Am. J. Kidney Dis. 52,
1070–1078 (2008).
47. Vikse, B. E., Irgens, L. M., Leivestad, T., Hallan, S. & Iversen, B. M. Low birth weight increases risk for end-stage renal disease. J.
Am. Soc. Nephrol. 19, 151–157 (2008).
48. Eriksson, J. G., Kajantie, E., Thornburg, K. & Osmond, C. Prenatal and maternal characteristics, and later risk for coronary heart
disease among women. Eur. J. Prev. Cardiol. 23, 385–390 (2016).
49. Painter, R. C. et al. Microalbuminuria in adults after prenatal exposure to the Dutch famine. J. Am. Soc. Nephrol. 16, 189–194
(2005).
50. White, S. L. et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am. J. Kidney
Dis. 54, 248–261 (2009).
51. Mu, M. et al. Birth weight and subsequent blood pressure: A meta-analysis. Arch. Cardiovasc. Dis. 105, 99–113 (2012).
52. Gjerde, A., Reisæter, A. V., Skrunes, R., Marti, H. P. & Vikse, B. E. Intrauterine growth restriction and risk of diverse forms of
kidney disease during the first 50 years of life. Clin. J. Am. Soc. Nephrol. 15, 1413–1423 (2020).
53. McCarthy, E. T., Sharma, M. & Savin, V. J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental
glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 2115–2121 (2010).
54. Sharma, M. et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophinlike cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl. Res. 166,
384–398 (2015).
55. Savin, V. J. et al. Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J. Immunol. Res. 2015,
714964 (2015).
56. Savin, V. J. et al. Multiple targets for novel therapy of FSGS associated with circulating permeability factor. Biomed. Res. Int. 2017,
6232616 (2017).
57. Hodgin, J. B. et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse
glomeruli. Diabetes 62, 299–308 (2013).
58. Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in
human diabetic nephropathy. Diabetes 58(2), 469–477 (2009).
59. Lu, T. C. et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 76, 63–71 (2009).

Scientific Reports |

(2021) 11:13260 |

https://doi.org/10.1038/s41598-021-92751-6

17
Vol.:(0123456789)

www.nature.com/scientificreports/
60. Tuttle, K. R. et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from a Phase 2 randomized controlled
clinical trial. Nephrol. Dial Transplant. 33, 1950–1959 (2018).
61. Koike, K. et al. Protective role of JAK/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction. Clin.
Immunol. 150, 78–87 (2014).
62. Gu, L. et al. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS 27, 1091–1098
(2013).
63. He, J. C. et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2
pathways. J. Clin. Invest. 114, 643–651 (2004).
64. Tao, J. et al. JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis. Kidney Int. 94, 795–808 (2018).
65. Weimbs, T., Olsan, E. E. & Talbot, J. J. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease. JAKSTAT
2, e23650 (2013).
66. Takakura, A. et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum. Mol.
Genet. 20, 4143–4154 (2011).
67. Yamada, K. et al. Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy. Kidney Int. Rep. 2,
1194–1207 (2017).
68. Srivastava, T. et al. Hyperfiltration-mediated injury in the remaining kidney of a transplant donor. Transplantation 102, 1624–1635
(2018).
69. Muzaale, A. D. et al. Risk of end-stage renal disease following live kidney donation. JAMA 311, 579–586 (2014).
70. Mjøen, G. et al. Long-term risks for kidney donors. Kidney Int. 86, 162–167 (2014).
71. Grams, M. E. et al. Kidney-failure risk projection for the living kidney-donor candidate. N. Engl. J. Med. 374, 411–421 (2016).
72. O’Keeffe, L. M. et al. Mid- and long-term health risks in living kidney donors: A systematic review and meta-analysis. Ann. Intern.
Med. 168, 276–284 (2018).
73. Ibrahim, H. N. et al. Renal function profile in white kidney donors: The first 4 decades. J. Am. Soc. Nephrol. 27, 2885–2893 (2016).
74. Massie, A. B. et al. Quantifying postdonation risk of ESRD in living kidney donors. J. Am. Soc. Nephrol. 28, 2749–2755 (2017).
75. Matas, A. J., Berglund, D. M., Vock, D. M. & Ibrahim, H. N. Causes and timing of end-stage renal disease after living kidney donation. Am. J. Transplant. 18, 1140–1150 (2018).
76. Sanna-Cherchi, S. et al. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int. 76,
528–533 (2009).
77. Westland, R., Schreude, M. F., Bökenkamp, A., Spreeuwenberg, M. D. & van Wijk, J. A. Renal injury in children with a solitary
functioning kidney—the KIMONO study. Nephrol. Dial. Transplant. 26, 1533–1541 (2011).
78. Westland, R., Kurvers, R. A., van Wijk, J. A. & Schreuder, M. F. Risk factors for renal injury in children with a solitary functioning
kidney. Pediatrics 131, e478–e485 (2013).
79. Argueso, L. R. et al. Prognosis of patients with unilateral renal agenesis. Pediatr. Nephrol. 6, 412–416 (1992).
80. Gubhaju, L. et al. Is nephrogenesis affected by preterm birth? Studies in a non-human primate model. Am. J. Physiol. Renal. Physiol.
297, F1668–F1677 (2009).
81. Sutherland, M. R. et al. Accelerated maturation, and abnormal morphology in the preterm neonatal kidney. J. Am. Soc. Nephrol.
22, 1365–1374 (2011).
82. Alcalay, N. I., Brantley, J. G., Sharma, M., Gooch, J. L. & Vanden Heuvel, G. B. Ectopic expression of the homeobox gene Cux-1
rescues calcineurin inhibition in mouse embryonic kidney cultures. Dev. Dyn. 236, 184–191 (2007).
83. Savin, V. J., Sharma, R., Lovell, H. B. & Weilling, D. J. Measurement of albumin reflection coefficient with isolated rat glomeruli.
J. Am. Soc. Nephrol. 3, 1260–1269 (1992).
84. Shankland, S. J., Pippin, J. W., Reiser, J. & Mundel, P. Podocytes in culture: Past, present, and future. Kidney Int. 72, 26–36 (2007).
85. Srivastava, T. et al. Fluid flow shear stress upregulates prostanoid receptor EP2, but not EP4 in murine podocytes. Prostaglandins
Other Lipid Mediat. 104–105, 49–57 (2013).
86. Srivastava, T. et al. Cyclooxygenase-2, Prostaglandin E2 and prostanoid receptor EP2 in fluid flow shear stress mediated injury in
solitary kidney. Am. J. Physiol. Renal. Physiol. 307, F1323–F1333 (2014).
87. Srivastava, T. et al. Mechanotransduction signaling in podocytes from fluid flow shear stress. Am. J. Physiol. Renal. Physiol. 314,
F22–F34 (2018).
88. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27–30 (2000).
89. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947–1951 (2019).

Acknowledgements

This work was supported in part by NIDDK R01DK107490 (Srivastava, Sharma), Kierznowski Family Charitable
Trust (Srivastava), Patton Trust Grant from Kansas City Area Life Sciences (Srivastava, Sharma), Katherine B
Richardson Grant (Srivastava, Sharma), Sam and Helen Kaplan Research Fund in Pediatric Nephrology (Alon,
Srivastava), funds from the Midwest Veterans Biomedical Research Foundation and KCVA Medical Center,
Kansas City, MO (Sharma) and the Grow Iowa Values Fund Grant (Mahajan). Mukut Sharma received support,
in part, from the Department of Veterans Affairs VA BX001037 during the period of these studies. Each author
has read and approved the final version of the manuscript and is prepared to take public responsibility for the
work. The Medical Writing Center at Children’s Mercy Hospital provided editing support for the manuscript.

Author contributions

These authors have been part of conceptual model of IL-6 family of cytokines in kidney disease and development, have made substantial contributions to this novel concept and design over the years, and have published
together for many years on this subject (T.S., D.P.H., R.E.G., T.J., Y.J., U.S.A., E.T.M., V.J.S., R.S. and M.S.). The
following authors played a key role in methodology and formal analysis (G.B.V., M.S., P.M., M.H.R., L.P., J.Z.,
V.C.B. and M.F.A.), data curation (T.S., L.P. and M.F.A.), writing—original draft preparation (T.S. and M.S.),
project administration (T.S. and M.S.), funding acquisition (T.S. and M.S.).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-021-92751-6.
Scientific Reports |
Vol:.(1234567890)

(2021) 11:13260 |

https://doi.org/10.1038/s41598-021-92751-6

18

www.nature.com/scientificreports/
Correspondence and requests for materials should be addressed to T.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2021

Scientific Reports |

(2021) 11:13260 |

https://doi.org/10.1038/s41598-021-92751-6

19
Vol.:(0123456789)

